Alamar Biosciences (NASDAQ:ALMR) Now Covered by JPMorgan Chase & Co.

Research analysts at JPMorgan Chase & Co. started coverage on shares of Alamar Biosciences (NASDAQ:ALMR) in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm set an “overweight” rating and a $30.00 price target on the stock. JPMorgan Chase & Co.‘s target price would indicate a potential upside of 25.63% from the company’s previous close.

ALMR has been the subject of a number of other reports. Wall Street Zen raised Alamar Biosciences to a “hold” rating in a report on Saturday, April 25th. TD Cowen started coverage on Alamar Biosciences in a research report on Tuesday. They issued a “buy” rating for the company. Finally, Stifel Nicolaus initiated coverage on Alamar Biosciences in a research report on Tuesday. They set a “buy” rating and a $28.00 price target for the company. Three equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $29.00.

Alamar Biosciences Stock Down 0.3%

Alamar Biosciences stock opened at $23.88 on Tuesday. Alamar Biosciences has a 1-year low of $21.50 and a 1-year high of $27.20.

Alamar Biosciences (NASDAQ:ALMR) last issued its quarterly earnings data on Friday, May 8th. The company reported ($1.74) earnings per share (EPS) for the quarter. The company had revenue of $26.04 million during the quarter.

Insider Activity at Alamar Biosciences

In other news, major shareholder Innovation Fund Gp Illumina II acquired 235,294 shares of the business’s stock in a transaction on Monday, April 20th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the completion of the purchase, the insider directly owned 507,076 shares of the company’s stock, valued at $8,620,292. This represents a 86.57% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Nicholas Naclerio acquired 235,294 shares of the business’s stock in a transaction on Monday, April 20th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $3,999,998.00. Following the purchase, the director directly owned 507,076 shares of the company’s stock, valued at $8,620,292. This represents a 86.57% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.